On the other hand, SLE and Sjogren’s syndrome patients develop autoantibodies to IFI16 in 29 and 70% of all cases, respectively (222, 223), implying a causative link, which is significant due to the reported AIM2 inhibition by IFI16 (224). Here, IFI16 is linked to Sjogren syndrome.